Valbiotis SA (FR:ALVAL)
:ALVAL
Want to see FR:ALVAL full AI Analyst Report?
ALVAL Stock Chart & Stats
€0.72
€0.05(3.27%)
At close: 4:00 PM EST
€0.72
€0.05(3.27%)
Day’s Range― - ―
52-Week Range€0.54 - €1.30
Previous CloseN/A
Volume46.53K
Average Volume (3M)112.19K
Market Cap
€23.69M
Enterprise Value€23.71M
Total Cash (Recent Filing)€8.68M
Total Debt (Recent Filing)€5.09M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding23,698,235
10 Day Avg. Volume162,174
30 Day Avg. Volume112,190
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.36
Price to Sales (P/S)18.17
P/FCF Ratio-2.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.36
Revenue Forecast (FY)€4.53M
Bulls Say, Bears Say
Bulls Say
Plant‑based Nutraceutical FocusValbiotis' core strategy centers on plant‑based nutraceuticals targeting metabolic and cardiovascular prevention. This aligns with durable structural trends toward preventive health and chronic disease management, supporting sustained market demand and differentiated product positioning over multiple years.
Commercial Traction: 2025 Revenue ReboundThe 2025 revenue rebound indicates the company can regain commercial traction after a down year, a durable sign that product sales and distribution can scale. If sustained, this helps absorb fixed costs, improve gross economics and validate market acceptance beyond short‑term fluctuations.
Manageable Leverage On Balance SheetDebt levels appear moderate (debt/equity ~0.73 in 2025) which, combined with a small headcount and lean structure, gives the company greater flexibility to pursue R&D and commercialization without immediate heavy debt servicing. This reduces near‑term solvency risk versus highly leveraged peers.
Bears Say
Persistent Losses And Negative Gross ProfitConsistent losses and negative gross profit across recent years show the core business has not yet reached sustainable unit economics. Negative gross margins imply the current scale does not support cost absorption, which threatens long‑term margin sustainability unless revenues rise materially or costs are restructured.
Recurring Cash Burn And Negative Free Cash FlowMulti‑year negative operating and free cash flow (FCF ~-€8.2M in 2025) means the business cannot self‑fund growth or R&D. This structural cash burn creates ongoing reliance on external financing, increasing dilution risk and constraining strategic choices over the medium term.
Volatile Revenue And Limited VisibilityLarge swings in revenue year‑to‑year indicate weak top‑line predictability, complicating capacity planning, cost absorption and partnership negotiations. Persistent volatility undermines margin improvement prospects and increases execution risk for scaling commercial operations over the next several quarters.
Valbiotis SA News
ALVAL FAQ
What was Valbiotis SA’s price range in the past 12 months?
Valbiotis SA lowest stock price was €0.54 and its highest was €1.30 in the past 12 months.
What is Valbiotis SA’s market cap?
Valbiotis SA’s market cap is €23.69M.
When is Valbiotis SA’s upcoming earnings report date?
Valbiotis SA’s upcoming earnings report date is Sep 24, 2026 which is in 107 days.
How were Valbiotis SA’s earnings last quarter?
Valbiotis SA released its earnings results on Mar 02, 2026. The company reported -€0.204 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.204.
Is Valbiotis SA overvalued?
According to Wall Street analysts Valbiotis SA’s price is currently Overvalued.
Does Valbiotis SA pay dividends?
Valbiotis SA does not currently pay dividends.
What is Valbiotis SA’s EPS estimate?
Valbiotis SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valbiotis SA have?
Valbiotis SA has 23,698,235 shares outstanding.
What happened to Valbiotis SA’s price movement after its last earnings report?
Valbiotis SA reported an EPS of -€0.204 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.971%.
Which hedge fund is a major shareholder of Valbiotis SA?
Currently, no hedge funds are holding shares in FR:ALVAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valbiotis SA
Valbiotis SA is a French company, established in 2014 and headquartered in Périgny, that specializes in the research and development of nutritional health products. Its primary focus is on preventing and managing metabolic and cardiovascular diseases. The company's pipeline includes several key candidates: TOTUM-63, currently in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, undergoing Phase II trials to address hypercholesterolemia; and TOTUM-854, which is in Phase II/III clinical development for arterial hypertension. Additionally, Valbiotis is developing TOTUM-448 to treat non-alcoholic fatty liver disease. The company maintains a strategic partnership with Nestlé Health Science.